IADR Abstract Archives
Antibiofilm and Mucoadhesive Potential of Semi-Solid Formulations Containing Natural Compounds
Objectives:
Candida albicans and non-albicans species are responsible for superficial and systemic infections in compromised hosts. Current antifungals are limited, involve adverse side effects and, above all, lead to drug resistance. Therefore, it seems reasonable to develop a safe, environmentally sustainable, low-cost and effective therapy against Candida biofilms. As a novel strategy for Candida spp. infection, this study aimed to explore the antibiofilm effect and the mucoadhesive potential of semi-solid formulations containing natural compounds.
Methods: Biofilms of Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis, and Candida tropicalis were grown in YNB medium supplemented with glucose in sterile plaques for 2 h. Then, the biofilms were subjected to the following formulations: 1) 2.5% tt-farnesol + 2.5% apigenin; 2) 10% naringenin and, 3) vehicle (without compounds). Candida cell concentrations were evaluated by counting of the colony-forming units (CFU) as well as their inhibition was confirmed by using scanning electron microscopy (SEM). Mucoadhesive work was evaluated by detachment of formulations from porcine oral mucosa using a texture analyzer (TA XT Plus, Stable Micro Systems; n=5).
Results: Biofilms were found to be susceptible to the formulations 1 and 2, demonstrating a ≥1 to 3-log10 (CFU) statistically significant decrease in their viability when compared to vehicle (ANOVA/Tukey). The anti-biofilm activity of the formulations was corroborated by SEM images, which evidenced a substantial reduction in the fungal growth and the disruption of the biofilm’s architecture and integrity. Formulations 1 and 2 had greater mucoadhesive work values when compared to vehicle (p=0.045; Kruskal-Wallis).
Conclusions:
The findings highlight the control of Candida biofilms and mucoadhesive potential of based on natural compounds semi-solid formulations and serve as a starting point to the characterization of new candidates to get rid of antibiotic-resistant biofilms.
Candida albicans and non-albicans species are responsible for superficial and systemic infections in compromised hosts. Current antifungals are limited, involve adverse side effects and, above all, lead to drug resistance. Therefore, it seems reasonable to develop a safe, environmentally sustainable, low-cost and effective therapy against Candida biofilms. As a novel strategy for Candida spp. infection, this study aimed to explore the antibiofilm effect and the mucoadhesive potential of semi-solid formulations containing natural compounds.
Methods: Biofilms of Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis, and Candida tropicalis were grown in YNB medium supplemented with glucose in sterile plaques for 2 h. Then, the biofilms were subjected to the following formulations: 1) 2.5% tt-farnesol + 2.5% apigenin; 2) 10% naringenin and, 3) vehicle (without compounds). Candida cell concentrations were evaluated by counting of the colony-forming units (CFU) as well as their inhibition was confirmed by using scanning electron microscopy (SEM). Mucoadhesive work was evaluated by detachment of formulations from porcine oral mucosa using a texture analyzer (TA XT Plus, Stable Micro Systems; n=5).
Results: Biofilms were found to be susceptible to the formulations 1 and 2, demonstrating a ≥1 to 3-log10 (CFU) statistically significant decrease in their viability when compared to vehicle (ANOVA/Tukey). The anti-biofilm activity of the formulations was corroborated by SEM images, which evidenced a substantial reduction in the fungal growth and the disruption of the biofilm’s architecture and integrity. Formulations 1 and 2 had greater mucoadhesive work values when compared to vehicle (p=0.045; Kruskal-Wallis).
Conclusions:
The findings highlight the control of Candida biofilms and mucoadhesive potential of based on natural compounds semi-solid formulations and serve as a starting point to the characterization of new candidates to get rid of antibiotic-resistant biofilms.